肿瘤治疗药物监测临床实施的障碍与机遇
本文综述肿瘤治疗中治疗药物监测(TDM)临床实施的障碍与机遇。肿瘤领域剂量个体化至关重要,剂量不足可致治疗失败和癌症进展,剂量过量可致严重不良反应。文章探讨采样策略、生物分析和给药决策支持等创新科学方法如何克服现有系统局限,促进TDM在肿瘤临床实践中的实施。
要点
- 肿瘤TDM临床实施面临与抗菌药物等成熟TDM领域不同的独特挑战
- 剂量不足可致治疗失败和癌症进展,剂量过量可致严重不良反应
- 采样策略、生物分析和给药决策支持等创新方法有望促进肿瘤TDM临床转化
核心结论
- 肿瘤领域剂量个体化至关重要,但TDM策略虽价值公认却鲜有临床转化。
- 采样策略、生物分析和给药决策支持等创新科学方法有望克服现有系统局限,促进TDM在肿瘤临床中的实施。
研究设计与样本
- 本文为综述,探讨肿瘤治疗药物监测临床实施的障碍与机遇,未报告系统检索范围。
主要发现
- 肿瘤临床设置不同于目前以TDM为基石治疗的领域(如抗菌药物),需考虑癌症治疗的特殊挑战。
- 剂量不足可致治疗失败和癌症进展,剂量过量可致粒细胞缺乏和中性粒细胞减少等严重限制治疗的副作用。
- 剂量不足和剂量过量均导致患者预后不良,并贡献于肿瘤领域仍可见的高死亡率。
临床怎么用
- 肿瘤TDM临床实施需借鉴成熟TDM领域的经验,同时考虑癌症治疗的特殊挑战。
- 可利用采样策略、生物分析和给药决策支持等创新方法促进TDM在肿瘤临床实践中的实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are few fields of medicine in which the individualisation of medicines is more important than in the area of oncology. Under-dosing can have significant ramifications due to the potential for therapeutic failure and cancer progression; by contrast, over-dosing may lead to severe treatment-limiting side effects, such as agranulocytosis and neutropenia. Both circumstances lead to poor patient prognosis and contribute to the high mortality rates still seen in oncology. The concept of dose individualisation tailors dosing for each individual patient to ensure optimal drug exposure and best clinical outcomes. While the value of this strategy is well recognised, it has seen little translation to clinical application. However, it is important to recognise that the clinical setting of oncology is unlike that for which therapeutic drug monitoring (TDM) is currently the cornerstone of therapy (e.g. antimicrobials). Whilst there is much to learn from these established TDM settings, the challenges presented in the treatment of cancer must be considered to ensure the implementation of TDM in clinical practice. Recent advancements in a range of scientific disciplines have the capacity to address the current system limitations and significantly enhance the use of anticancer medicines to improve patient health. This review examines opportunities presented by these innovative scientific methodologies, specifically sampling strategies, bioanalytics and dosing decision support, to enable optimal practice and facilitate the clinical implementation of TDM in oncology.
引用
- Menz BD, Stocker SL, Verougstraete N, et al. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol. 2020. PMID: 32430968. doi:10.1111/bcp.14372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。